# Protagenic Therapeutics (PTIX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PTIX
## Company Profile
- Ticker: PTIX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 1 USD
- Market cap: Not available USD
- Last updated: 2026-09-03
## Business Overview
Protagenic Therapeutics is a biotechnology company focused on neuropsychiatric and stress-related disorders. Its story is built around the idea that peptide-based or related approaches can address difficult CNS conditions.
## Why The Stock Is Moving

As of Sep 3, 2026, PTIX closed down 4.76% at $1.00. No new same-company headline was identified in the current news window.

## Geographic Base

Protagenic is headquartered in the United States and listed on NASDAQ. It sits in small-cap neuroscience biotechnology.

## Business Model

The company depends on preclinical and early clinical validation, translational credibility, and capital support. Investors typically watch early data, pipeline prioritization, and whether the company can narrow its story into a viable CNS thesis.

## Landscape Position

Protagenic occupies a speculative neuroscience niche within biotech. It is a high-risk story where platform proof matters more than near-term commercial scale.

## Future Catalysts

- Protagenic’s catalysts are neuropeptide and CNS programs, with any update that clarifies whether the company can still produce meaningful development progress. The stock needs a cleaner clinical path.

## Recent News
- 2026-05-19 08:15 EST — [Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-engages-floyd-regulatory-strategic-consulting-as-regulatory-affairs-advisor-and-danforth-health-as-strategic-operations-partner) — Source: Protagenic Therapeutics
- 2026-04-23 08:15 EST — [Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-appoints-industry-veteran-bill-nichols-jr-as-president-to-accelerate-advancement-of-first-in-class-tcap-pathway-therapy-pt00114) — Source: Protagenic Therapeutics
- 2026-03-17 08:00 EST — [Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-completes-phytanix-separation-strengthens-balance-sheet-and-repositions-the-company-around-pt00114) — Source: Protagenic Therapeutics
- 2026-03-10 08:00 EST — [Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market](https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-upgrades-from-otc-pink-to-otcqb-venture-market) — Source: Protagenic Therapeutics
- 2025-12-09 08:46 EST — [Results from Phase 1 Multiple-Dose Study of PT00114](https://biopharmsignal.com/news/PTIX/results-from-phase-1-multiple-dose-study-of-pt00114) — Source: Protagenic Therapeutics